Agile Therapeutics Inc
AGRXDelisted Jun 3, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001261249
Agile Therapeutics Inc was delisted on Jun 3, 2024; its insiders filed their last Form 4 on Aug 26, 2024; 21 institutions reported holding it in 13F filings for Q4 2023, worth $496.2K in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Agile Therapeutics Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Agile Therapeutics Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Barbari Sharon | Director | 0 | Aug 26, 2024 | 0 |
| Altomari Alfred | Chief Executive Officer | 0 | Aug 26, 2024 | 0 |
| Gilmore Geoffrey | Chief Administrative Officer | 0 | Aug 26, 2024 | 0 |
| Fischer Seth H. Z. | Director | 0 | Aug 26, 2024 | 0 |
| Coiante Scott M | Chief Financial Officer | 0 | Aug 26, 2024 | 0 |
| Hubbard John W | Director | 0 | Aug 26, 2024 | 0 |
| Korner Paul | Chief Medical Officer | 0 | Aug 26, 2024 | 0 |
| Conway Robert G | Chief Supply Chain Officer | 0 | Aug 26, 2024 | 0 |
| Carson Sandra | Director | 0 | Aug 26, 2024 | 0 |
| Torrente Josephine | Director | 0 | Aug 26, 2024 | 0 |
| Welsh Amy | Chief Commercial Officer | 0 | Aug 26, 2024 | 0 |
| Butch Jason | Principal Accounting Officer | – | Nov 14, 2022 | 0 |
| Tursi James Patrick | Director | 2,066 | Jun 10, 2022 | 0 |
| Shetty Ajit | Director | 2,241 | Jun 10, 2022 | 0 |
| Reilly Dennis | Chief Financial Officer | 285,130 | Jan 20, 2022 | 0 |
| Edelman Joseph | 10% Owner | 21,654,485Indirect | Oct 15, 2021 | 0 |
| Perceptive Advisors LLC | 10% Owner | 21,654,485Indirect | Oct 15, 2021 | 0 |
| Perceptive Life Sciences Master Fund Ltd | 10% Owner | 21,654,485Indirect | Oct 15, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 29, 2022 (view filing)8:30 AM ET | Aug 26 | 3 days | Altomari AlfredChief Executive Officer | PPurchase | +50.0K | $0.45 | +$22.5K | +348.6%64.3K after | |
| Oct 15, 2021 (view filing)4:05 PM ET | Oct 13 | 2 days | Edelman Joseph and 2 others10% Owner | PPurchase | +5.73M | $0.85 | +$4.87M | +36.0%21.7M after | |
| Oct 15, 2021 (view filing)4:05 PM ET | Oct 13 | 2 days | Edelman Joseph and 2 others10% Owner | PPurchase | +2.69M | – | – | –2.69M after | Derivative |
| Oct 14, 2021 (view filing) | Oct 13 | 1 day | Reilly DennisChief Financial Officer | PPurchase | +58.8K | – | – | +26.0%285.1K after | |
| Oct 14, 2021 (view filing) | Oct 13 | 1 day | Reilly DennisChief Financial Officer | PPurchase | +29.4K | – | – | –29.4K after | Derivative |
| Oct 14, 2021 (view filing) | Oct 13 | 1 day | Altomari AlfredChief Executive Officer | PPurchase | +58.8K | – | – | +11.4%573.7K after | |
| Oct 14, 2021 (view filing) | Oct 13 | 1 day | Altomari AlfredChief Executive Officer | PPurchase | +29.4K | – | – | –29.4K after | Derivative |
| Jul 29, 2021 (view filing) | Jul 29 | Same day | Altomari AlfredChief Executive Officer | PPurchase | +26.2K | $1.26 | +$33.0K | +5.4%514.9K after | |
| Jul 28, 2021 (view filing) | Jul 27 | 1 day | Reilly DennisChief Financial Officer | PPurchase | +50.0K | $1.08 | +$54.0K | +28.4%226.3K after |